ArticleInternational journal of nanomedicine2018
A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- PLGA nanoparticles in otoprotection and inner ear regeneration: a new frontier in nanomedicine for hearing disorders.RSC advances · 2025Review
- Understanding the Mechanisms Driving Fibrosis Following Cochlear Implantation-Lessons from Other Tissues.Cells · 2025Review
- Mesoporous Silica Nanoparticles for Quercetin-Controlled Delivery to Protect Cisplatin-Induced Ototoxicity.ACS applied bio materials · 2025Article
- Recent Advances in Functionalized Nanoparticles for Targeted and Controlled Inner Ear Therapy via Localized Cochlear Delivery.Journal of audiology & otology · 2025Review
- Programmable NIR Responsive Nanocomposite Enables Noninvasive Intratympanic Delivery of Dexamethasone to Reverse Cisplatin Induced Hearing Loss.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cochlear Mechanics Are Preserved After Inner Ear Delivery of Gold Nanoparticles.International journal of molecular sciences · 2024Article
- Lysophosphatidic acid exerts protective effects on HEI-OC1 cells against cytotoxicity of cisplatin by decreasing apoptosis, excessive autophagy, and accumulation of ROS.Cell death discovery · 2023Article
- Review
- Efficiency of a dexamethasone nanosuspension as an intratympanic injection for acute hearing loss.Drug delivery · 2022Article
- Liquid Crystalline Nanoparticles Conjugated with Dexamethasone Prevent Cisplatin Ototoxicity In Vitro.International journal of molecular sciences · 2022Article
- Nanomaterials for Inner Ear Diseases: Challenges, Limitations and Opportunities.Materials (Basel, Switzerland) · 2022Review
- The Use of Nanoparticles in Otoprotection.Frontiers in neurology · 2022Review
- Polydatin activates the Nrf2/HO-1 signaling pathway to protect cisplatin-induced hearing loss in guinea pigs.Frontiers in pharmacology · 2022Article
- [Development of novel drug carrier via round window membrane].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2021Review
- Nanocarriers for Inner Ear Disease Therapy.Frontiers in cellular neuroscience · 2021Review
- Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity.Expert opinion on drug metabolism & toxicology · 2020Review
- Current Strategies to Combat Cisplatin-Induced Ototoxicity.Frontiers in pharmacology · 2020Review
- New molecular therapies for the treatment of hearing loss.Pharmacology & therapeutics · 2019Review
- Developments in Bio-Inspired Nanomaterials for Therapeutic Delivery to Treat Hearing Loss.Frontiers in cellular neuroscience · 2019Review
- Local Drug Delivery for Prevention of Hearing Loss.Frontiers in cellular neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe delivery of treatment agents to inner ear with drug delivery system (DDS) has been under investigation to overcome the limitations of the conventional therapeutic agents in curing or alleviating the cisplatin ototoxicity.
methodsIn the present study, a novel targeted dexamethasone (DEX)-loaded DDS, A666-DEX-NP, was constructed for prevention from cisplatin-induced hearing loss. A666-(CLEPRWGFGWWLH) peptides specifically bind to prestin, which is limited to the outer hair cells (OHCs). HEI-OC1 and cisplatin-treated guinea pigs (12 mg/kg, intraperitoneal) were used as in vitro and in vivo models for investigating the targeting and protective efficiency against cisplatin.
resultsAs expected, compared to A666-unconjugated nanoparticles (NP), A666-conjugated coumarin 6-labeled NP showed active targeting to OHCs. Furthermore, A666-coumarin 6-labeled NP could be significantly internalized by HEI-OC1 cells via the A666-prestin interaction. This facilitated the uptake of cells pretreated with A666-DEX-NP, followed by the cisplatin-treated group, which led to enhanced cell viability, reduced apoptotic properties, and decreased reactive oxygen species levels as compared to cells pretreated with DEX or DEX-NP, 4 hours in advance of cisplatin treatment. In cisplatin-treated guinea pigs, pretreatment with A666-DEX-NP effectively preserved OHCs and showed significant hearing protection at 4, 8, and 16 kHz as compared to pretreatment with saline, DEX, or DEX-NP formulation.
conclusionThis OHC-targeting DDS provides a novel strategy for DEX application that can be potentially used to combat cisplatin ototoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.